For Shire, Life After Adderall XR? Yes
Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.
You may also be interested in...
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.
Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader
If successful, Sanofi-Aventis' attempt to acquire Genzyme would catapult the company into the orphan drug business, marking Big Pharma's most aggressive strategy in the space to date.